COVID-19 Pandemic in Women–Rheumatologist’s Perspective
COVID-19 has caused unprecedented challenges to every field. Rheumatic diseases (RD) are more common in women compared with men. Patients with RD are predisposed to infections both because of their disease and immunosuppressive medication. The severity of COVID-19 in women is less as compared with men among the general population. It is not known if the risk is higher in women with RD compared with other women. Currently, published data of COVID-19 in RD suggests similar or mildly increased risk in patients with RD but sex disaggregated data is not available. In this article, we review the current evidence of COVID-19 in RD with an emphasis on women.
05 October 2020 (online)
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 World Health Organization. Organización Mundial de la salud - OMS. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int/. Accessed August 22, 2020
- 2 Government of India. #IndiaFightsCorona COVID-19 in India, Corona Virus Tracker. Available at: https://www.mygov.in/covid-19. Accessed August 22, 2020
- 3 Qian J, Zhao L, Ye R-Z, Li X-J, Liu Y-L. Age-dependent gender differences of COVID-19 in mainland China: comparative study. Clin Infect Dis 2020 (e-pub ahead of print). doi: https://doi.org/10.1093/cid/ciaa683
- 4 Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL, Impact of sex and gender on COVID-19 outcomes in Europe. Biology of Sex Differences2020;(e-pub ahead of print). doi: https://doi.org/10.1186/s13293-020-00304-9
- 5 Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents 2020; 34 (02) 339-343
- 6 Spagnolo PA, Manson JE, Joffe H. Sex and gender differences in health: what the COVID-19 pandemic can teach us. Ann Intern Med 2020; (e-pub ahead of print) DOI: 10.7326/M20-1941.
- 7 McGonagle D, Sharif K, O’Regan A, Bridgewood C, The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmunity Reviews2020 (e-pub ahead of print). Doi: https://doi.org/10.1016/j.autrev.2020.102537
- 8 Maggi E, Canonica GW, Moretta L. COVID-19: Unanswered questions on immune response and pathogenesis. J Allergy Clin Immunol 2020; 146 (01) 18-22
- 9 Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 2020; 39 (07) 2085-2094
- 10 Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R, Montecucco C. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheumatol 2020;(e-pub ahead of print). doi: https://doi.org/10.1002/art.41388
- 11 Emmi G, Bettiol A, Mattioli I, et al SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmunity Reviews 2020 (e-pub ahead of print). doi: https://dx.doi.org/10.1016%2Fj.autrev.2020.102575
- 12 Pablos JL, Abasolo L, Alvaro-Gracia JM. et al. RIER investigators group. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis 2020; (e-pub ahead of print) DOI: 10.1136/annrheumdis-2020-217763.
- 13 Gianfrancesco M, Hyrich KL, Al-Adely S. et al. COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020; 79 (07) 859-866
- 14 Ye C, Cai S, Shen G. et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis 2020; 79 (08) 1007-1013
- 15 D’Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’ Ann Rheum Dis 2020 (e-pub ahead of print). doi: https://doi.org/10.1136/annrheumdis-2020-217888
- 16 Oran DP, Topol EJ. Prevalence of asymptomatic SARSCoV- 2 infection: a narrative review. Ann Intern Med 2020 (e-pub ahead of print). doi: https://doi.org/10.7326/m20-3012
- 17 Guan WJ, Ni ZY, Hu Y. et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720
- 18 Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-1242
- 19 Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G, Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis. Clinical Chemistry and Laboratory Medicine2020 (e-pub ahead of print). doi: https://doi.org/10.1515/cclm-2020-0369
- 20 Tu H, Tu S, Gao S, Shao A, Sheng J, Current epidemiological and clinical features of COVID-19: a global perspective from China. Journal of Infection2020 (e-pub ahead of print). doi: https://dx.doi.org/10.1016%2Fj.jinf.2020.04.011
- 21 Ahmed S, Zimba O, Gasparyan AY. Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad. Clin Rheumatol 2020; 39 (09) 2529-2543
- 22 Zhang Y, Xiao M, Zhang S. et al. Coagulopathy and antiphospholipid antibodies in patients with covid-19. N Engl J Med 2020; 382 (17) e38
- 23 Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 2020; 39 (07) 2055-2062
- 24 Pouletty M, Borocco C, Ouldali N. et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis 2020; 79 (08) 999-1006
- 25 Chowdhury MS, Rathod J, Gernsheimer J, A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19. Academic Emergency2020 (e-pub ahead of print). doi: https://doi.org/10.1111/acem.14005
- 26 Tang W, Cao Z, Han M. et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369: m1849
- 27 Boulware DR, Pullen MF, Bangdiwala AS. et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 2020; 383 (06) 517-525
- 28 Xu X, Han M, Li T. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020; 117 (20) 10970-10975
- 29 Toniati P, Piva S, Cattalini M. et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmunity Reviews 2020; (e-pub ahead of print) DOI: 10.1016/j.autrev.2020.102568.
- 30 Guaraldi G, Meschiari M, Cozzi-Lepri A, et al Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol2020(e-pub ahead of print). doi: https://Doi.org/10.1016/S2665-9913(20)30173-9
- 31 Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc 2020; 83 (06) 534-536
- 32 Huet T, Beaussier H, Voisin O. et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020; 2: 393-400
- 33 Horby P, Lim WS, Emberson JR. et al. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 - Preliminary Report. N Engl J Med 2020; (e-pub ahead of print) DOI: 10.1056/NEJMoa2021436.
- 34 Stebbing J, Phelan A, Griffin I, et al COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases 2020;(e-pub ahead of print). doi: https://doi.org/10.1016/S1473-3099(20)30132-8
- 35 Favalli EG, Biggioggero M, Maioli G, Caporali R, Baricitinib for COVID-19: a suitable treatment? The Lancet Infectious diseases 2020;( e-pub ahead of print). doi: https://doi.org/10.1016/S1473-3099(20)30262-0
- 36 Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 2020; 81 (02) 318-356
- 37 Li L, Li L, Zhang W. et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA -. JAMA 2020; 324 (05) 460-470
- 38 Piechotta V, Chai KL, Valk SJ, et al Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database of Systematic Reviews 2020 (e-pub ahead of print). doi: https://doi.org/10.1002/14651858.CD013600.pub2
- 39 Pharmaceutical Technology. Biocon’s drug Itolizumab gets approval to treat Covid-19. Available at: https://www.pharmaceutical-technology.com/news/biocon-itolizumab-approval/. Accessed August 22, 2020
- 40 Mikuls TR, Johnson SR, Fraenkel L. et al. American College of Rheumatology guidance for the management of adult patients with rheumatic disease during the COVID-19 pandemic. Arthritis Rheumatol 2020; (e-pub ahead of print) DOI: 10.1002/art.41301.
- 41 Price E, MacPhie E, Kay L. et al. Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic. Clin Med (Lond) 2020; 20 (03) 256-261 (Northfield Il)
- 42 COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders. Nice 2020. Available at:https://www.nice.org.uk/guidance/ng167. Accessed July 20, 2020
- 43 Shenoy P, Ahmed S, Paul A, Skaria TG, Joby J, Alias B. Switching to teleconsultation for rheumatology in the wake of the COVID-19 pandemic: feasibility and patient response in India. Clin Rheumatol 2020; 39 (09) 2757-2762